May 13, 2021
Business News

Gyroscope Therapeutics Files Registration Statement for Proposed Initial Public Offering in the United States


LONDON–()–Gyroscope Therapeutics, a clinical-stage gene therapy company focused on treating diseases of the eye, today announced it has filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering (“IPO”) in the United States of its American Depositary Shares (“ADSs”), each representing one ordinary share.

All ADSs to be sold in the proposed IPO will be offered by Gyroscope. Gyroscope has applied to list its ADSs on the Nasdaq Global Select Market under the ticker symbol “VISN.” The number of ADSs to be offered and the pricing terms for the proposed IPO have not yet been…



Click here to view the original article.

Related Posts

You might also like ...

AON Splash Image
Finance of America Reports First Quarter 2021 Results
Farmers Edge Reports First Quarter 2021 Results
U.S. Department of Health and Human Services Selects Box for Cloud Content Management